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ABSTRACT 
Purpose: To assess the potential advantage of intensity-modulated radiotherapy (IMRT) over 3D-conformal 
radiotherapy (3D-CRT) planning in postoperative adjuvant radiotherapy for patients with gastric carcinoma. Methods 
and materials: In a retrospective study, for plan comparison, dose distribution was recalculated in 15 patients treated 
with 3D-CRT on the contoured structures of same CT images using an IMRT technique. 3D-conformal plans with three 
fields and four-fields were compared with seven-field dynamic IMRT plans. The different plans were compared by 
analyzing the dose coverage of planning target volume using TV95, Dmean, uniformity index, conformity index and 
homogeneity index parameters. To assess critical organ sparing, Dmean, Dmax, dose to one-third and two-third volumes of 
the OARs and percentage of volumes receiving more than their tolerance doses were compared. Results: The average 
dose coverage values of PTV with 3F-CRT and 4F-CRT plans were comparable, where as IMRT plans achieved better 
target coverage(p<0.001) with higher conformity index value of 0.81±0.07 compared to both the 3D-CRT plans. The 
doses to the liver and bowel reduced significantly (p<0.001) with IMRT plans compared to other 3D-CRT plans. For all 
OARs the percentage of volumes receiving more than their tolerance doses were reduced with the IMRT plans. 
Conclusion: This study showed that a better target coverage and significant dose reduction to OARs could be achieved 
with the IMRT plans. The IMRT can be preferred with caution for organ motion. The authors are currently studying 
organ motion in the upper abdomen to use IMRT for patient treatment. © 2010 Biomedical Imaging and Intervention 
Journal. All rights reserved. 
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INTRODUCTION 
Gastric cancer is the second most common cancer 
worldwide, with a frequency that varies greatly across 
different geographic locations [1]. Despite the decreasing 
worldwide incidence, gastric cancer accounts for 3% to 
10% of all cancer related deaths [2].
 In spite of technical 
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advances in surgery and adjuvant therapy, the mortality 
associated with gastric cancer is prevailing. Patients with 
localized node negative gastric cancer have 5-year 
survival rates that approach 75% when treated with 
surgery alone [3]. This is in contrast to patients with 
lymph node involvement, in whom survival rates range 
from 10% to 30% [4, 5, 6]. Preliminary studies of 
adjuvant chemo-radiotherapy showed promising results 
in patients resected with curative intent [7, 8].  
The target delineation as well as the treatment 
technique of radiation dose delivery to the post operative 
stomach remains complex. This is due to the large 
planned target volume (PTV) and surrounding mobile 
parts of bowel and other critical organs, such as liver, 
kidneys and spinal cord. Recent data indicate that post-
operative chemo-radiotherapy improves clinical outcome 
by improving the relapse-free survival in gastric cancer 
and that acute toxicity is acceptable [9]. Data on late side 
effects, however, are scarce. Renal function impairment 
represents one of the most serious late complications 
following abdominal radiotherapy.   
The CT images with 3-dimensional (3D) planning 
software help in displaying the 3D-dose distribution at 
different levels in the PTV. In conventional 3D-CRT for 
stomach cancer, very commonly three-field technique 
(3F-CRT) or four-field technique (4F-CRT) is used. All 
the fields are shaped with MLC and either physical or 
dynamic wedges are used to achieve optimal three-
dimensional dose distribution with minimal degree of 
dose inhomogeneity through forward treatment planning. 
Early and late radiation induced complications are 
directly related to the total dose delivered, fractionation 
scheme, radiation treatment technique and patient 
anatomy. Several institutions have reported the use of 
different techniques to improve the dose distribution 
within the PTV [10-13]. 
Despite all efforts in the conventional method of 
planning, the surrounding normal tissue of PTV and 
other critical organs at risk still receives considerable 
doses in the final plan. In Intensity Modulated 
Radiotherapy (IMRT) it is possible to overcome this 
problem by achieving desired dose distribution with its 
ability to provide sharp dose gradients at the junction of 
target volume and the adjacent critical organs. In order to 
explore the advantages of IMRT treatment and extend it 
to the gastric cancer patients, a retrospective study was 
carried out by the first author (KMM) at his previous 
institution on 15 patients of gastric cancer treated with 
3D-CRT. In this article the authors describe the planning 
methods used and show the comparison of results for 4F-
CRT and IMRT plans of a representative patient. They 
also furnish DVH comparison results of conventional 3F-
CRT, 4F-CRT and dynamic IMRT for all 15 cases.  
MATERIALS AND METHODS 
3D Radiation Treatment Planning System (RTPS) 
Eclipse (version 6.5, Varian Ag, USA) with Helios 
inverse planning software was used for treatment 
planning. High energy Linear Accelerator Clinac 2300 
CD (Varian Ag, USA) having 120 leaf millennium MLC 
was used for the delivery of treatments. Fifteen patients 
planned and treated with three/four field 3DCRT were 
taken up for a retrospective study by re-planning with 
dynamic IMRT technique and comparing the dose 
distributions in PTV and organs at risk. For all the cases 
radiation was given in 25 fractions of 1.8 Gy to a total 
dose of 45 Gy in 5 weeks. CT images of 5mm thickness 
at different transverse sections away from the mid plane 
were taken to create a 3D image. Initially the 3D forward 
planning of 3F-CRT with three fields (AP and two 
laterals) was done for 15 patients in conventional way. 
Then 4F-CRT planning with four fields (AP, two laterals 
and PA) was done for each patient. In both cases, 
appropriate wedges were used to obtain uniform dose 
distribution in the target volume. The beam energies (6 
and 15MV), beam weightings and MLC leaf positions 
were optimized by forward planning to reduce the doses 
to the critical organs and achieve a better homogeneous 
dose distribution in the PTV.   
Following the 3DCRT plans, dynamic IMRT plans 
were created on the same CT images with structures. 
Seven fields of 6MV energy with equal separation of 
gantry angles were used. A constraints template was 
created and applied to all the 15 patient plans. Wherever 
required and achievable, the constraints were changed to 
obtain possible minimum doses to critical organs without 
compromising the PTV coverage of at least 95% dose to 
95% of PTV volume.  
Comparison parameters: To asses the target 
coverage and normal tissue sparing the following 
parameters were used. 
1.  A uniformity index was used and defined as:  
95
5
D
D
UI = (1)  
Where D5  and D95 are the minimum doses 
delivered to 5% and 95%, respectively of the 
PTV as previously described by Wang et al. [14] 
and Kesheng et al. [15]. In addition, to assess 
target coverage, the mean and maximum doses 
to PTV, percentage of target volume receiving 
at least 95% of the prescribed dose TV95(%) 
and the dose to 1% of target volume D1(%) 
were calculated.   
2.  Radiation dose homogeneity index (HI), which 
was defined by Nutting et al. [16] and Pezner et 
al. [17] as the difference in PTV dose between 
D1 and D99 divided by the prescription dose was 
calculated. Smaller HI corresponds to more 
homogeneous dose distribution in PTV. 
3.  The conformity index, CI was calculated by 
using the following formula [18].   
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where, TV95 is the volume of target covered by 
the 95% isodose line, TV is the total target 
volume and V95 is the volume of tissue covered 
by the 95% isodose line. The value of CI varies 
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between 0 to 1 and a value close to 1 gives 
better conformity of dose to the PTV. 
4.  The sparing of the organs at risk was evaluated 
by comparing their maximum and mean doses. 
D2/3 and D1/3, defined as the dose received by 
2/3 and 1/3 volumes of the organ respectively, 
were also analysed for tolerance limits [19, 20]. 
5.  The percentage of volumes of organs at risk 
(OARs) receiving a dose more than their 
corresponding tolerance limit (V>TL) were 
compared. 
The values of the above parameters of 15 cases 
planned by conventional forward planning with 3F-CRT, 
4F-CRT and the dynamic IMRT technique were 
compared with the help of their dose volume histograms. 
Statistical analysis was performed with the two-tailed 
paired t-test. A p-value of p<0.05 was considered 
statistically significant.  
RESULTS 
All three planning techniques produced acceptable 
dose distributions to the planned target volume. All the 
dose coverage parameters of PTV for the 3F-CRT and 
4F-CRT plans showed similar and comparable values 
without significant differences. The isodose distributions 
obtained on an axial slice at the isocenter plane of a 
representative patient for 4F-CRT and IMRT are shown 
in Figure 1. The plan comparison DVH curves for PTV 
and OARs of the same patient for 4F-CRT and IMRT are 
shown in Figure 2. The analysed data of fifteen patients 
with the mean doses to the PTV and comparison of dose 
coverage with 3D-CRT and IMRT treatment plans is 
shown in Table 1. The results indicate that there was a 
statistically significant and considerable difference in the 
dose coverage of PTV with IMRT (p<0.001) compared 
to both 3D-CRT plans. The average lower values of SD, 
UI, HI and higher values of CI for IMRT plans compared 
to the 3F-CRT and 4F-CRT plans confirms the 
advantage of IMRT plans over both 3D-CRT plans.  
The dose coverage of OARs with 3F-CRT, 4F-CRT 
and IMRT plans along with the p-values are shown in 
Table 2. The average mean dose values of liver were less 
in 4F-CRT plans compared with that in 3F-CRT plans. 
There was however, a significant (p<0.001) dose 
reduction in liver with IMRT plans compared to both 
3D-CRT plans. 
The average mean values and other doses of both 
the kidneys and the spine with the 3F-CRT plans were 
lower than that with the 4F-CRT plans. The reduction of 
liver dose in 4F-CRT and reduction of doses in kidneys 
and spine with 3F-CRT plans were attributed to the 
addition of the PA field in the 4F-CRT plans. The IMRT 
plans were able to achieve lower values of doses in the 
right kidney compared to that of both 3D-CRT plans, 
whereas the dose values in the left kidney were 
comparable. Similarly the dose values in the spinal cord 
with IMRT plans were lower than that with the 4F-CRT 
plans and slightly higher than that with the 3F-CRT plans.  
In the case of bowel, all the mean dose values were 
similar and comparable in both 3D-CRT plans and they 
were significantly reduced in IMRT (p<0.001) plans. In 
all OARs the percentage of volumes receiving more than 
their tolerance doses were reduced significantly (p<0.001) 
with IMRT plans compared with both 3D-CRT plans.  
DISCUSSION 
The toxicity associated with adjuvant radiotherapy 
using conventional 3DCRT techniques is significant. 
This is because of the standard target prescribed dose of 
45 Gy well exceeds the tolerance of surrounding critical 
organs, namely kidneys and liver. Thus one has to 
compromise either in prescription to treat at tolerance 
doses of normal tissues rather than to the specific 
tumoricidal dose or in tailoring of the conventional 
treatment volumes. In both cases, local control and 
survival may be compromised. As IMRT delivers more 
conformal dose to the target by sparing surrounding 
critical structures, it allows complete target coverage to 
full dose and improves locoregional control and reduces 
toxicity. A number of studies have demonstrated the 
superiority of the physical dose distribution of IMRT 
compared to 3DCRT in the treatment of gastric cancers 
[21, 22]. 
The comparison of 3F-CRT and 4F-CRT plans 
showed that the dose coverage of PTV in both cases was 
similar and comparable. But as expected from the use of 
the additional PA field in 4F-CRT, the dose to liver was 
less compared to the 3F-CRT plan, while the doses to the 
kidneys and spinal cord were slightly more in 4F-CRT 
plans than in 3F-CRT plans. However, this marginal 
dose differences in OARs would not give overall clinical 
significance between the two techniques. Depending 
upon the shape and the size of the PTV and critical 
organs, by comparing the DVH values, either one of the 
plans can be chosen. 
In this study, the PTV from IMRT plans showed a 
systematic and significant improvement in terms of 
target coverage and homogeneity compared to 3D-CRT 
plans. Conformity index is used to evaluate the clinical 
evidence of better treatments. The results showed that 
IMRT treatment plans give considerable improvement of 
dose conformity to PTV with higher value of CI 
compared to both 3F-CRT and 4F-CRT plans. Improved 
conformity may help to deliver higher doses to the PTV 
without delivering more doses to the surrounding normal 
tissue. This was clearly demonstrated by the isodose 
distributions and DVH curves shown in Figures 1 and 2, 
respectively. The uniformity index values calculated for 
the target volume also showed significant advantage of 
IMRT plans over 3D-CRT plans. 
With respect to all OARs, IMRT is able to keep the 
mean dose below their tolerance levels in contrast with 
3D-CRT. This dose reduction in non-target structures 
without compromising the dose in the target volumes 
could lead to additional clinical advantages, because side 
effects during or following treatment might be reduced. 
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Figure 1  Isodose curves on an axial slice at isocenter plane of a representative patient for 4F-CRT and IMRT. 
The lower part of the figure shows the isodose distribution on the coronal and sagittal plane of the 
corresponding slice. 
 
 
 
 
 
 
Figure 2  Comparison of DVH curves of 4F-CRT and IMRT plans of a representative patient for (a) PTV, Liver 
and Bowel, (b) Left kidney, Right Kidney and Spinal cord. 
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Table 1  Comparison of the average dose parameters of 15 patients for the PTV among the three planning 
techniques. 
P-Value 
PTV 3F-CRT  4F-CRT  IMRT  3F-CRT vs 
IMRT 
4F-CRT vs 
IMRT 
3F-CRT vs
4F-CRT 
Dmean (%) 
Dmax (%) 
D1% (%) 
TV95% (%) 
 101.80  ±  1.31 
 108.96  ±  1.45 
 107.00  ±  1.48 
 98.79  ±  1.31 
 101.85  ±  1.02 
 108.81  ±  1.03 
 106.85  ±  1.11 
 98.95  ±  1.07 
 100.44  ±  0.45 
 106.09  ±  1.28 
 103.89  ±  0.77 
 97.94  ±  1.29 
<0.001 
<0.001 
<0.001 
0.080 
<0.001 
<0.001 
<0.001 
0.026 
0.914 
0.751 
0.699 
0.697 
SD (%) 
UI 
CI 
HI 
 2.43  ±  0.50 
 1.08  ±  0.02 
 0.62  ±  0.04 
 0.12  ±  0.02 
 2.37  ±  0.54 
 1.08  ±  0.02 
 0.61  ±  0.04 
 0.11  ±  0.02 
 1.91  ±  0.37 
 1.06  ±  0.01 
 0.81  ±  0.07 
 0.10  ±  0.02 
0.003 
<0.001 
0.039 
<0.001 
0.011 
0.005 
<0.001 
0.108 
0.753 
0.388 
0.839 
0.692 
Dmean, mean dose; Dmax, maximum dose; D1%, dose to 1% of target volume; TV95%, dose to 95% of target volume; UI, 
uniformity index; CI, conformity index; HI, homogeneity index; SD, standard deviation of dose in the PTV. 
 
 
 
 
 
Table 2  Comparison of average dose distribution in the Organs at risk (OARs) for a prescribed dose of 45Gy for 
15 patients. 
Mean Dose ± SD (%)  P-Value 
OAR 
Tolerance 
Dose limit 
TD 5/5 
(Gy) 
3F-CRT 4F-CRT  IMRT 
3F-CRT 
vs 
IMRT 
4F-CRT 
vs 
IMRT 
3F-CRT 
vs 
4F-CRT 
Liver 
 D max 
 D mean 
 D 2/3 
 D 1/3 
 V >30Gy 
 
 
 
30 
35 
50 
 
 48.1  ± 1.0 
 28.0  ± 3.9 
 25.4  ± 6.0 
 36.9  ± 3.4 
 26.8  ± 5.3 
 
 47.7  ± 0.8 
 26.9  ± 3.9 
 23.4  ± 6.1 
 34.1  ± 3.7 
 23.0  ± 5.3 
 
 47.0  ± 1.0 
 23.7  ± 3.5 
 17.6  ± 4.8 
 28.1  ± 3.5 
 13.1  ± 3.5 
 
0.008 
<0.004 
<0.001 
<0.001 
<0.001 
 
0.038 
0.025 
0.007 
<0.001 
<0.001 
 
0.318 
0.428 
0.368 
0.047 
0.055 
Right Kidney 
 D max 
 D mean 
 D 2/3 
 D 1/3 
 V >23Gy 
 
 
 
23 
30 
36 
 
 44.9  ± 2.4 
 12.0  ± 2.6 
 6.3  ±  3.5 
 13.6  ± 1.8 
 5.7  ±  4.0 
 
 44.8  ± 4.0 
 12.9  ± 2.5 
 6.1  ±  3.7 
 16.4  ± 2.9 
 6.3  ±  4.0 
 
 35.8  ± 3.5 
 11.6  ± 1.5 
 7.3  ±  1.8 
 12.3  ± 1.2 
 2.4  ±  1.3 
 
<0.001 
0.594 
0.317 
0.021 
0.005 
 
<0.001 
0.100 
0.246 
<0.001 
0.001 
 
0.920 
0.353 
0.877 
0.004 
0.687 
Left Kidney 
 D max 
 D mean 
 D 2/3 
 D 1/3 
 V >23Gy 
 
 
 
23 
30 
36 
 
 44.2  ± 2.1 
 13.7  ± 3.1 
 10.1  ± 2.8 
 14.3  ± 2.2 
 5.5  ±  3.3 
 
 44.8  ± 2.2 
 15.0  ± 2.6 
 11.5  ± 3.8 
 17.3  ± 2.1 
 6.7  ±  3.8 
 
 37.7  ± 4.5 
 14.5  ± 2.1 
 11.1  ± 2.7 
 17.3  ± 2.5 
 7.3  ±  2.1 
 
<0.001 
0.388 
0.333 
0.002 
0.270 
 
<0.001 
0.610 
0.775 
0.989 
0.739 
 
0.463 
0.227 
0.284 
<0.001 
0.368 
Spinal cord 
 D max 
 D mean 
 D 2/3 
 D 1/3 
 V >45Gy 
 
 
 
45 
50 
50 
 
 22.8  ± 9.9 
 9.8  ±  1.9 
 5.8    ±  4.4 
 13.1  ± 1.7 
 0.0  ±  0.0 
 
 25.1  ± 7.5 
 11.6  ± 2.2 
 6.3  ±  4.9 
 16.4  ± 1.8 
 0.0  ±  0.0 
 
 25.2  ± 2.2 
 11.0  ± 1.9 
 4.6  ±  4.1 
 16.0  ± 2.1 
 0.0  ±  0.0 
 
0.369 
0.086 
0.448 
<0.001 
0.115 
 
0.974 
0.395 
0.330 
0.358 
0.153 
 
0.474 
0.018 
0.796 
<0.001 
0.944 
Bowel 
 D max 
 D mean 
 D 2/3 
 D 1/3 
 V >40Gy 
 
 
 
40 
45 
50 
 
 49.0  ± 0.8 
 27.5  ± 4.4 
 22.1  ± 6.4 
 36.6  ± 4.9 
 12.9  ± 4.6 
 
 48.7  ± 0.7 
 27.0  ± 4.3 
 22.0  ± 5.5 
 35.8  ± 5.7 
 13.2  ± 4.7 
 
 47.1  ± 0.7 
 24.6  ± 3.6 
 17.9  ± 2.9 
 31.5  ± 2.4 
 9.8  ±  3.3 
 
<0.001 
0.058 
0.029 
0.001 
0.046 
 
<0.001 
0.099 
0.015 
0.011 
0.030 
 
0.297 
0.785 
1.000 
0.684 
0.857 
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On the other hand, dose reduction in the OAR volumes 
could allow additional dose escalation to the target 
structures. Therefore the capability of dose conformity of 
IMRT is clinically beneficial to the patients of gastric 
cancer. 
With IMRT treatments, the mean dose to the liver 
was reduced by 9.6% and 5% when compared with the 
3F-CRT and 4F-CRT plans respectively. This reduction 
of dose may appear small, but the mean values of D2/3, 
D1/3 and percentage of volume receiving more than the 
tolerance limit were reduced considerably compared to 
both 3D-CRT plans, which helps in reducing the toxicity. 
In the case of kidneys and spinal cord, though there 
was a smaller difference in the mean doses with the plans 
of three techniques, mean values of D2/3,D1/3 and 
percentage of volumes receiving more than their 
tolerance limit were reduced significantly with IMRT 
(p<0.0001) plans. The tendency of reduction in doses to 
OARs with IMRT obtained in this study was similar to 
that of earlier studies reported by Milano et al. [23] and 
Kataria et al. [24]. 
The bowel contour consisting of small and large 
intestines was done and no constraints were given in 
IMRT plans. Since it is a mobile organ, the authors 
wanted to verify the dose distribution and compare the 
values with these three techniques. The results showed 
that all the dose parameters of bowel in three field and 
four field conformal plans were comparable and IMRT 
plans reduced them considerably. The reduction of dose 
in OARs with IMRT plans may be due to the use of more 
number of fields with appropriate angle selection, which 
causes reduction of entrance and exit dose to those 
organs. 
CONCLUSION 
IMRT plans improve the homogeneity and 
conformity of dose distribution in the target volume. The 
uniformity index and standard deviation (SD) values also 
confirmed a better 3D dose homogeneity in the PTV with 
the IMRT technique. With this method, the maximum 
dose coverage around the PTV has reduced considerably. 
In the treatment of gastric malignancies IMRT reduces 
the mean dose and the dose above threshold to critical 
normal tissues, particularly to the liver and kidneys. With 
this technique, the desired dose distribution can be 
achieved due to its ability to provide sharp dose gradients 
at the junction of target volume and the adjacent OARs. 
Overall, the doses to all the OARs were lower for IMRT 
plans and were in acceptable limits. The advantages of 
IMRT plans include both improved planning target 
volume coverage and improved sparing of critical organs.  
In conclusion, this study suggests a dosimetric 
benefit of IMRT over conventional 3D-CRT planning 
and indicates the importance of IMRT in the adjuvant 
treatment of gastric cancer. The study helped the authors 
to understand the role of IMRT in detail and created 
confidence to consider the same to treat the patients with 
carcinoma of gastric cancers. However, the superiority of 
IMRT over conventional 3D-CRT must be mitigated 
with the caution for organ motion. Currently the authors 
are studying the effect of organ motion in the upper 
abdomen as a prerequisite for the use of IMRT for 
patient treatment to further evaluate doses received by 
these moving organs. 
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